

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>14</b>
<b>1. Basics of Drug Delivery to the Central Nervous System .....</b>	<b>16</b>
<b>Introduction .....</b>	<b>16</b>
<b>Historical evolution of drug delivery for CNS disorders.....</b>	<b>16</b>
<b>Neuroanatomical and neurophysiological basis of drug delivery.....</b>	<b>17</b>
The cerebrospinal fluid .....	17
The extracellular space in the brain .....	18
Neurotransmitters.....	18
<b>Neuropharmacology relevant to drug delivery.....</b>	<b>20</b>
Introduction to neuropharmacology.....	20
Pharmacokinetics.....	20
<i>Absorption and distribution of drugs .....</i>	<i>20</i>
<i>Drug metabolism and elimination.....</i>	<i>21</i>
Pharmacodynamics .....	21
<i>Receptors .....</i>	<i>21</i>
Sites of drug action in the CNS .....	21
<i>Receptors coupled to guanine nucleotide binding proteins .....</i>	<i>22</i>
<i>Acetylcholine receptor channels .....</i>	<i>22</i>
<i>Dopamine receptors .....</i>	<i>22</i>
<i>GABA receptor channels.....</i>	<i>23</i>
<i>Glutamate receptor channels.....</i>	<i>23</i>
<i>Non-competitive NMDA antagonists.....</i>	<i>23</i>
<i>Serotonin receptors.....</i>	<i>24</i>
<i>G-protein coupled receptors .....</i>	<i>24</i>
In vivo study of drug action in the CNS in human patients .....	24
<i>Electroencephalography.....</i>	<i>24</i>
<i>Brain imaging.....</i>	<i>25</i>
Chronopharmacology as applied to the CNS .....	25
<b>2. Blood Brain Barrier .....</b>	<b>28</b>
<b>Introduction .....</b>	<b>28</b>
<b>Features of the blood-brain barrier relevant to CNS drug delivery.....</b>	<b>28</b>
The neurovascular unit .....	28
Functions of the BBB .....	29
<i>BBB as an anatomical as well as physiological barrier .....</i>	<i>29</i>
<i>BBB as a biochemical barrier .....</i>	<i>30</i>
<i>Genomics and proteomics of BBB.....</i>	<i>30</i>
Other neural barriers.....	31
<i>Blood-cerebrospinal fluid barrier .....</i>	<i>31</i>
<i>Blood nerve barrier .....</i>	<i>31</i>
<i>Blood-retinal barrier.....</i>	<i>31</i>
<i>Blood-labyrinth barrier.....</i>	<i>31</i>
<b>Passage of substances across the blood-brain barrier .....</b>	<b>32</b>
Transporters localized in the BBB.....	32
<i>Glucose transporter.....</i>	<i>33</i>
<i>Amino acid transporters.....</i>	<i>34</i>
<i>Ionic transporter.....</i>	<i>34</i>
<i>Efflux transport systems .....</i>	<i>34</i>
BBB-specific enzymes.....	35
Receptor-mediated transcytosis .....	36
Lysophosphatidic acid-mediated increase in BBB permeability .....	36
Folate transport system .....	37
Molecular biology of the BBB .....	37
Transport of peptides and proteins across the BBB .....	37
<i>Passage of leptin across the BBB.....</i>	<i>37</i>
<i>Passage of cytokines across the BBB .....</i>	<i>38</i>
<i>Passage of hormones across the BBB .....</i>	<i>38</i>
<i>Passage of enzymes across the BBB .....</i>	<i>39</i>
<i>Drugs that cross the BBB by binding to plasma proteins.....</i>	<i>39</i>
Current concepts of the permeability of the BBB .....	39
<b>Factors that increase the permeability of the BBB .....</b>	<b>40</b>
BBB disruption as adverse effect of vaccines for CNS disorders .....	40
CNS disorders that affect the permeability of BBB .....	41
<i>Neurodegenerative disorders.....</i>	<i>42</i>
<i>Mitochondrial encephalopathies .....</i>	<i>43</i>
<i>Multiple sclerosis.....</i>	<i>43</i>

Central nervous system injuries.....	43
Epilepsy.....	44
Cerebrovascular disease.....	44
Infections.....	45
Autoimmune disorders.....	45
BBB and primary brain tumors.....	45
BBB and cerebral metastases.....	46
<b>Testing permeability of the BBB.....</b>	<b>46</b>
In vitro models of BBB.....	46
In vivo study of BBB.....	47
Brain imaging.....	47
In silico prediction of BBB.....	48
Relevance of the BBB penetration to pharmacological action.....	49
BBB penetration and CNS drug screening.....	50
CERENSE <sup>SM</sup> .....	50
Transthyretin monomer as a marker of blood-CSF barrier disruption.....	50
Evaluation of BBB permeability by brain imaging.....	50
Biomarkers of disruption of blood-brain barrier.....	51
<b>Future directions for research on the BBB.....</b>	<b>51</b>
Application of genomics and proteomics to the study of BBB.....	52
Use of neural stem cells to construct the blood brain barrier.....	52
<b>Strategies to cross the BBB.....</b>	<b>53</b>

### **3. Methods of Drug Delivery to the CNS..... 54**

<b>Introduction.....</b>	<b>54</b>
<b>Routes of drug delivery to the brain.....</b>	<b>55</b>
Delivery of drugs to the brain via the nasal route.....	55
Nasal delivery of insulin-like growth factor-I.....	56
Nasal delivery of midazolam.....	56
Nasal delivery of hypocretin.....	57
Intranasal administration of IFN beta-1b.....	57
Nasal delivery of thyrotropin-releasing hormone by nanoconstructs.....	57
Nasal delivery of neuroprotective drugs for stroke.....	58
Transdermal drug delivery for neurological disorders.....	58
Drug delivery to the brain via inner ear.....	59
Invasive neurosurgical approaches.....	59
Intraarterial drug delivery to the brain.....	59
Direct injection into the CNS substance or CNS lesions.....	60
Intraventricular injection of drugs.....	60
Intrathecal drug delivery.....	61
Retrograde delivery to the brain via the epidural venous system.....	62
Devices for drug delivery to the CNS.....	62
<b>Strategies for drug delivery to the CNS across the BBB.....</b>	<b>63</b>
Increasing the permeability (opening) of the BBB.....	64
Osmotic opening of the BBB.....	64
Focal disruption of BBB by ultrasound.....	64
Chemical opening of the BBB.....	65
Cerebral vasodilatation to open the BBB.....	65
Use of nitric oxide donors to open the BBB.....	65
Manipulation of the sphingosine 1-phosphate receptor system.....	66
Pharmacological strategies to facilitate transport across the BBB.....	66
2B-Trans <sup>TM</sup> technology.....	66
ABC efflux transporters and penetration of the BBB.....	67
Carrier-mediated drug delivery across the BBB.....	67
G-Technology®.....	68
Glycosylation Independent Lysosomal Targeting.....	69
Inhibition of P-glycoprotein to enhance drug delivery across the BBB.....	69
Modification of the drug to enhance its lipid solubility.....	69
Monoclonal antibody fusion proteins.....	70
Neuroimmunophilins.....	71
Peptide-mediated transport across the BBB.....	71
Prodrug bioconversion strategies and their CNS selectivity.....	72
Role of the transferrin-receptor system in CNS drug delivery.....	73
Transport of small molecules across the BBB.....	73
Transport across the BBB by short chain oligoglycerolipids.....	73
Transvascular delivery across the BBB.....	74
Trojan horse approach.....	74
Use of receptor-mediated transcytosis to cross the BBB.....	75
Cell-based drug delivery to the CNS.....	76
Activated T lymphocytes.....	77
Microglial cells.....	77

<i>Neural stem cells</i> .....	77
Drug delivery to the CNS by using novel formulations.....	77
<i>Crystalline formulations</i> .....	77
<i>Liposomes</i> .....	78
<i>Monoclonal antibodies</i> .....	79
<i>Microspheres</i> .....	79
<i>Microbeads</i> .....	80
Brain-targeted chemical delivery systems .....	80
<b>Nanotechnology-based drug delivery to CNS .....</b>	<b>81</b>
Nanoparticles for drug delivery across the BBB .....	81
<i>Penetration of BBB by nanoparticles coated with polysorbate 80</i> .....	82
<i>NanoDel™ technology for crossing the BBB</i> .....	82
<i>Masking BBB-limiting characteristics by nanotechnology</i> .....	82
<i>Peptide-nanoparticle conjugates for crossing the BBB</i> .....	83
<i>Nanovesicles for transport across BBB</i> .....	83
Nanotechnology-based devices and implants for CNS .....	83
<b>Biochip implants for drug delivery to the CNS.....</b>	<b>84</b>
Controlled-release microchip .....	84
Retinal implant chip .....	84
<b>Convection-enhanced delivery to the CNS .....</b>	<b>85</b>
<b>Systemic administration of drugs for CNS effects .....</b>	<b>85</b>
Sustained and controlled release drug delivery to the CNS .....	85
<i>Fast dissolving oral selegiline</i> .....	87
Choice of the route of systemic delivery for effect on the CNS disorders .....	87
<b>Methods of delivery of biopharmaceuticals to the CNS .....</b>	<b>88</b>
Delivery of biopharmaceuticals across the BBB .....	88
Methods of delivery of peptides for CNS disorders .....	88
<i>Challenges for delivery of peptides across the BBB</i> .....	89
<i>Transnasal administration of neuropeptides</i> .....	89
<i>Direct delivery of neuropeptides into the brain</i> .....	89
<i>Alteration of properties of the BBB for delivery of peptides</i> .....	90
<i>Molecular manipulations of peptides to facilitate transport into CNS</i> .....	90
<i>CNS delivery of peptides via conjugation to biological carriers</i> .....	91
<i>Delivery of conopeptides to the brain</i> .....	91
Delivery of neurotrophic factors to the nervous system.....	92
<i>Systemic administration of NTFs</i> .....	93
<i>Delivery systems to facilitate crossing of the BBB by NTFs</i> .....	94
<i>Use of microspheres for delivery of neurotrophic factors</i> .....	95
<i>Intracerebroventricular injection</i> .....	95
<i>Direct application of NTFs to the CNS</i> .....	96
<i>Intrathecal administration</i> .....	96
<i>Implants for delivery of neurotrophic factors</i> .....	96
<i>Use of neurotrophic factor mimics</i> .....	97
<b>Use of microorganisms for therapeutic entry into the brain.....</b>	<b>98</b>
Bacteriophages as CNS therapeutics.....	98
<b>Intracellular drug delivery in the brain .....</b>	<b>99</b>
<b>Local factors in the brain affecting drug action.....</b>	<b>99</b>
<b>Methods for testing drug delivery to the CNS.....</b>	<b>99</b>
Animal models for testing drug delivery .....	99
Screening for drug-P-gp interaction at BBB .....	100
<b>4. Delivery of Cell, Gene and Antisense Therapies to the CNS.....</b>	<b>102</b>
<b>Introduction .....</b>	<b>102</b>
<b>Cell therapy of neurological disorders .....</b>	<b>102</b>
Methods for delivering cell therapies in CNS disorders .....	102
<i>Encapsulated cells</i> .....	103
<i>Genetically modified stem cells for metachromatic leukodystrophy</i> .....	104
<i>CNS neotissue implant</i> .....	104
<i>CNS delivery of cells by catheters</i> .....	104
<i>Subarachnoid delivery of stem cells</i> .....	105
<i>Intravascular administration</i> .....	105
<b>Gene therapy techniques for the nervous system .....</b>	<b>106</b>
Introduction .....	106
Methods of gene transfer to the nervous system.....	107
AAV vector mediated gene therapy for neurogenetic disorders.....	108
Ideal vector for gene therapy of neurological disorders .....	108
Promoters of gene transfer.....	108
Routes of delivery of genes to the nervous system.....	109
<i>Direct injection into CNS</i> .....	109
<i>Introduction of the genes into cerebral circulation</i> .....	110
<i>Introduction of genes into cerebrospinal fluid</i> .....	110

<i>Intravenous administration of vectors</i> .....	110
<i>Delivery of gene therapy to the peripheral nervous system</i> .....	111
Cell-mediated gene therapy of neurological disorders .....	111
<i>Neuronal cells</i> .....	111
<i>Neural stem cells and progenitor cells</i> .....	111
<i>Astrocytes</i> .....	111
<i>Cerebral endothelial cells</i> .....	112
<i>Implantation of genetically modified encapsulated cells into the brain</i> .....	112
<i>Genetically modified bone marrow cells</i> .....	112
Nanoparticles as non-viral vectors for CNS gene therapy .....	113
Applications of gene therapy for neurological disorders.....	113
Companies involved in cell/gene therapy of neurological disorders .....	114
<b>Antisense therapy of CNS disorders</b> .....	<b>115</b>
Delivery of antisense oligonucleotides to the CNS .....	116
Delivery of oligonucleotides cross the BBB .....	117
Cellular delivery systems for oligonucleotides .....	117
High-flow microinfusion into the brain parenchyma .....	118
Systemic administration of peptide nucleic acids .....	118
Introduction of antisense compounds into the CSF Pathways .....	118
Intrathecal administration of antisense compounds .....	119
Intracerebroventricular administration of antisense oligonucleotides.....	119
Nanoparticle-based delivery of antisense therapy to the CNS.....	120
Methods of delivery of ribozymes .....	120
<b>Delivery aspects of RNAi therapy of CNS disorders</b> .....	<b>121</b>
Delivery of siRNA to the CNS .....	121
<b>Future drug delivery strategies applicable to the CNS</b> .....	<b>121</b>
<b>5. Drug Delivery in the Treatment of CNS Disorders</b> .....	<b>124</b>
<b>Parkinson's disease</b> .....	<b>124</b>
Drug delivery systems for Parkinson's disease .....	125
<i>Duodenal levodopa infusion</i> .....	127
<i>Transdermal drug delivery for PD</i> .....	127
<i>Transdermal dopamine agonists for Parkinson's disease</i> .....	127
<i>Transdermal administration of other drugs for Parkinson's disease</i> .....	129
<i>Intracerebral administration of GDNF</i> .....	129
Cell therapy for Parkinson's disease .....	129
<i>Human dopaminergic neurons for PD</i> .....	131
<i>Graft survival-enhancing drugs</i> .....	131
<i>Xenografting porcine fetal neurons</i> .....	131
<i>Encapsulated cells for PD</i> .....	132
<i>Stem cells for PD</i> .....	132
<i>Engineered stem cells for drug delivery to the brain in PD</i> .....	134
<i>Human retinal pigment epithelium cells for PD</i> .....	134
<i>Delivery of cells for PD</i> .....	135
Gene therapy for Parkinson disease.....	135
<i>Rationale</i> .....	135
<i>Techniques of gene therapy for PD</i> .....	136
<i>Prospects of gene therapy for Parkinson's disease</i> .....	139
<i>Companies developing gene therapy for PD</i> .....	140
RNAi therapy of Parkinson's disease .....	140
<b>Alzheimer disease</b> .....	<b>141</b>
Drug delivery for Alzheimer disease .....	141
Blood-brain partitioning of an AMPA receptor modulator .....	142
Clearing amyloid through the BBB.....	142
Delivery of the passive antibody directly to the brain.....	142
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	143
Intranasal delivery of nerve growth factor to the brain .....	143
Nanoparticle-based drug delivery for Alzheimer's disease.....	143
<i>Perispinal etanercept</i> .....	144
Slow release implant of an AChE inhibitor .....	144
Transdermal drug delivery in Alzheimer's disease.....	144
Trojan-horse approach to prevent build-up of A $\beta$ aggregates.....	145
Cell and gene therapy for Alzheimer disease.....	145
<i>NGF gene therapy</i> .....	145
<i>Nepriylsin gene therapy</i> .....	146
RNAi therapy of Alzheimer's disease.....	147
<b>Huntington's disease</b> .....	<b>147</b>
Treatment of Huntington's disease .....	147
Drug delivery in Huntington's disease .....	148
Gene therapy of Huntington's disease.....	148
<i>Encapsulated genetically engineered cellular implants</i> .....	148

<i>Viral vector mediated administration of neurotrophic factors</i> .....	148
<i>RNAi therapeutics for the treatment of HD</i> .....	148
<b>Amyotrophic lateral sclerosis</b> .....	<b>148</b>
Treatment of ALS.....	149
Drug delivery in ALS.....	149
Gene and antisense therapy of amyotrophic lateral sclerosis .....	150
<i>Neurotrophic factor gene therapies of ALS</i> .....	150
<i>Antisense therapy of ALS</i> .....	152
<i>RNAi therapy of amyotrophic lateral sclerosis</i> .....	152
<b>Drug delivery for CNS involvement in Hunter syndrome</b> .....	<b>152</b>
<b>Cerebrovascular disease</b> .....	<b>153</b>
Treatment of stroke .....	153
Drug delivery in stroke .....	154
<i>Intraarterial administration of tissue plasminogen activator in stroke</i> .....	154
Drug delivery for prevention of restenosis of carotid arteries .....	155
<i>Modified NO donors</i> .....	156
<i>In-stent restenosis</i> .....	156
<i>Targeted local anti-restenotic drug delivery</i> .....	157
<i>Catheter-based drug delivery for restenosis</i> .....	157
<i>Stents for prevention of restenosis</i> .....	157
<i>Drug-eluting stents</i> .....	158
<i>Antisense approach to prevent restenosis</i> .....	159
Drug-eluting stents for the treatment of intracranial atherosclerosis.....	159
Tissues transplants for stroke.....	159
<i>Transplant of encapsulated tissue secreting neurotrophic factors</i> .....	160
Cell therapy for stroke .....	160
<i>Stem cell transplant into the brain</i> .....	160
<i>Immortalized cell grafts for stroke</i> .....	161
<i>Intravenous infusion of marrow stromal cells</i> .....	161
<i>Intravenous infusion of umbilical cord blood stem cells</i> .....	161
<i>Future of cell therapy for stroke</i> .....	162
Gene therapy of cerebrovascular diseases.....	162
<i>Gene transfer to cerebral blood vessels</i> .....	162
<i>NOS gene therapy for restenosis</i> .....	163
Gene therapy for cerebral ischemia .....	164
<i>Gene therapy of strokes with a genetic component</i> .....	165
Drug delivery to intracranial aneurysms.....	165
Drug delivery for vasospasm following subarachnoid hemorrhage .....	166
<i>Intrathecal tissue plasminogen activator</i> .....	167
<i>Gene therapy for vasospasm</i> .....	167
<b>Drug delivery in multiple sclerosis</b> .....	<b>168</b>
An electronic device for self injection of interferon beta-1a.....	169
Oral therapies for MS .....	169
Antisense and RNAi approaches to MS .....	169
Cell therapy for multiple sclerosis.....	170
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i> .....	170
<i>Embryonic stem cells and neural precursor cells for MS</i> .....	170
Gene therapy for multiple sclerosis .....	171
<b>Drug delivery in epilepsy</b> .....	<b>171</b>
Routes of administration of antiepileptic drugs.....	172
<i>Controlled-release preparations of carbamazepine</i> .....	172
<i>Intravenous carbamazepine</i> .....	172
<i>Various methods of delivery of diazepam</i> .....	173
Methods of delivery of novel antiepileptic therapies .....	173
<i>Regulated activation of prodrugs</i> .....	173
<i>Use of neuronal membrane transporter</i> .....	173
<i>Delivery of the antiepileptic conopeptides to the brain</i> .....	173
<i>Nasal administration of AEDs</i> .....	174
<i>Intracerebral administration of phenytoin</i> .....	174
The role of drug delivery in status epilepticus .....	174
Cell therapy of epilepsy .....	175
Gene therapy for epilepsy .....	176
<i>Gene therapy for neuroprotection in epilepsy</i> .....	176
Concluding remarks on drug delivery in epilepsy.....	177
<b>Drug delivery for pain</b> .....	<b>177</b>
Intranasal delivery of analgesics .....	178
<i>Intranasal administration of morphine</i> .....	178
<i>Intranasal morphine derivatives</i> .....	179
<i>Intranasal fentanyl</i> .....	179
<i>Intranasal buprenorphine</i> .....	180
<i>Intranasal ketamine</i> .....	180

<i>Intranasal ketorolac</i> .....	180
Delivery of analgesics by inhalation .....	181
Spinal delivery of analgesics.....	182
<i>Epidural dexamethasone</i> .....	184
<i>Epidural morphine</i> .....	184
<i>Relief of pain by intrathecal ziconotide</i> .....	184
<i>Intrathecal neostigmine</i> .....	185
<i>Intrathecal prostaglandin antagonists</i> .....	185
<i>Intrathecal fadolmidine</i> .....	185
<i>Intrathecal siRNA for relief of neuropathic pain</i> .....	186
<i>Concluding remarks on intrathecal delivery of analgesic agents</i> .....	186
Intracerebroventricular drug delivery for pain.....	186
<i>Delivery of analgesics to the CNS across the BBB</i> .....	186
<b>Drug delivery for migraine.....</b>	<b>187</b>
Management of migraine .....	187
Novel drug delivery methods for migraine .....	188
<i>Nasal formulations for migraine</i> .....	189
<i>Sublingual spray for migraine</i> .....	190
<i>Needle-free drug delivery for migraine</i> .....	190
<b>Relief of spasticity by intrathecal baclofen .....</b>	<b>190</b>
<b>Drug delivery for brain tumors .....</b>	<b>191</b>
Methods for evaluation of anticancer drug penetration into brain tumor.....	191
Innovative methods of drug delivery for glioblastoma multiforme.....	191
Anticancer agents with increased penetration of BBB.....	192
Local delivery of chemotherapeutic agents into the tumor.....	193
<i>Carmustine biodegradable polymer implants</i> .....	193
<i>Fibrin glue implants containing anticancer drugs</i> .....	193
<i>Biodegradable microspheres containing 5-FU</i> .....	194
<i>Nanoparticles for delivery of drugs to brain tumors across BBB</i> .....	194
<i>Convection-enhanced delivery</i> .....	195
Delivery of antibody-based anticancer therapy by ultrasound BBB disruption.....	195
Targeted monoclonal antibodies conjugated with liposomes .....	196
<i>Immunoliposomes</i> .....	196
<i>Lipid-coated microbubbles as a delivery vehicle for taxol</i> .....	196
<i>Thermoliposomes containing cytotoxic drugs</i> .....	196
Introduction of the chemotherapeutic agent into the CSF pathways.....	196
<i>Intrathecal chemotherapy</i> .....	196
<i>Intraventricular chemotherapy for meningeal cancer</i> .....	197
Increasing the permeability of blood-tumor barrier to anticancer drugs.....	197
<i>Disruption of BBB</i> .....	197
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB</i> .....	198
<i>Modulating efflux transporters to enhance chemotherapy penetration</i> .....	199
<i>PDE5 inhibitors for enhancing tumor permeability to chemotherapy</i> .....	199
Intraarterial chemotherapy .....	200
Interstitial delivery of dexamethasone for reduction of peritumor edema .....	200
Photodynamic therapy for chemosensitization .....	200
Boron neutron capture therapy .....	201
Gene therapy for glioblastoma multiforme. ....	202
<i>Single-chain antibody-targeted adenoviral vectors</i> .....	203
<i>Peptides targeted to glial tumor cells</i> .....	203
<i>Antiangiogenic gene therapy</i> .....	203
<i>RNAi gene therapy of brain cancer</i> .....	204
<b>Drug delivery for traumatic brain injury .....</b>	<b>204</b>
Cell therapy of traumatic brain injury .....	204
<i>Gene therapy for traumatic brain injury</i> .....	205
<b>Drug delivery for spinal cord injury .....</b>	<b>205</b>
Administration of neurotrophic factors for spinal cord injury .....	206
Cell therapy for spinal cord injury .....	206
<i>Transplantation of glial cells for SCI</i> .....	206
<i>Fetal neural grafts for SCI</i> .....	206
<i>Embryonic stem cells for SCI</i> .....	207
<i>Schwann cell transplants for SCI</i> .....	207
<i>Olfactory glial cells for SCI</i> .....	207
<i>Marrow stromal cells for SCI</i> .....	208
<i>Intravenous injection of stem cells for spinal cord repair</i> .....	208
<i>Combinatorial approach for regeneration in SCI</i> .....	208
<i>Cell therapy of syringomyelia</i> .....	209
<i>Gene therapy of spinal cord injury</i> .....	209
<b>Drug delivery for retinal disorders.....</b>	<b>209</b>
<i>Age-related macular degeneration</i> .....	210
<i>TheraSight ocular brachytherapy system for wet AMD</i> .....	210

<i>Combretastatin A4P for myopic macular degeneration</i> .....	210
<i>Gene therapy for AMD</i> .....	211
<i>Anti-VEGF approach to AMD</i> .....	211
<i>Delivery of aptamers for treatment of AMD</i> .....	211
Stem cell therapy for retinitis pigmentosa .....	212
Proliferative retinopathies .....	212
<b>Drug delivery in CNS infections</b> .....	<b>213</b>
Drug delivery in neuroAIDS.....	213
<b>6. Markets for Drug Delivery in CNS Disorders</b> .....	<b>214</b>
<b>Introduction</b> .....	<b>214</b>
Methods of calculation of CNS drug delivery markets.....	214
<b>Markets for CNS drug delivery technologies</b> .....	<b>214</b>
Drug delivery share in selected CNS markets.....	215
CNS share of drug delivery technologies .....	215
Geographical distribution of CNS drug delivery markets .....	216
<b>Impact of improved drug delivery on CNS drug markets</b> .....	<b>216</b>
Neurodegenerative disorders.....	216
<i>Alzheimer's disease</i> .....	216
<i>Parkinson's Disease</i> .....	217
<i>Huntington's disease</i> .....	217
<i>Amyotrophic lateral sclerosis</i> .....	217
Epilepsy.....	218
Migraine and other headaches .....	218
Stroke .....	218
Spinal cord injury.....	219
Multiple sclerosis.....	219
Brain tumors .....	219
<b>Limitations of the current drug delivery technologies for CNS</b> .....	<b>219</b>
<b>Unmet needs in CNS drug delivery technologies</b> .....	<b>220</b>
<b>Future strategies for expanding CNS drug delivery markets</b> .....	<b>221</b>
Education of neurologists .....	221
Demonstration of the advantages of the newer methods of delivery .....	221
Rescue of old products by novel drug delivery methods .....	222
Facilitation of the approval process of new drugs .....	222
<b>7. Companies</b> .....	<b>224</b>
<b>Introduction</b> .....	<b>224</b>
<b>Profiles</b> .....	<b>224</b>
<b>Collaborations</b> .....	<b>299</b>
<b>8. References</b> .....	<b>302</b>

## Tables

Table 1-1: Landmarks in the development of drug delivery to the CNS .....	16
Table 2-1: Proteins expressed at the neurovascular unit.....	29
Table 2-2: Transporters that control penetration of molecules across the BBB .....	33
Table 2-3: Enzymes that control the penetration of molecules across the BBB .....	35
Table 2-4: Factors that increase the permeability of the BBB.....	40
Table 2-5: Diseases that affect the BBB.....	41
Table 3-1: Various methods of drug delivery to the central nervous system .....	54
Table 3-2: Drugs available for intrathecal administration .....	61
Table 3-3: Strategies for drug delivery to the CNS across the BBB .....	64
Table 3-4: Specific inhibitors of P-glycoprotein in clinical development .....	69
Table 3-5: Molecules attached to Trojan horses injected intravenously for CNS effect.....	74
Table 3-6: Examples of controlled and sustained release drug delivery for CNS disorders .....	86
Table 3-7: Novel methods of delivery of drugs for CNS disorders .....	88
Table 3-8: Indications for the clinical applications of NTFs in neurologic disorders .....	92
Table 3-9: Methods for delivery of neurotrophic factors to the CNS .....	93
Table 4-1: Methods for delivering cell therapies in CNS disorders.....	103
Table 4-2: Classification of methods of gene therapy.....	106
Table 4-3: Methods of gene transfer as applied to neurologic disorders .....	107
Table 4-4: Potential indications for gene therapy of neurologic disorders .....	113
Table 4-5: Companies developing cell/gene therapies for CNS disorders .....	114
Table 4-6: Methods of antisense delivery as applied to the CNS.....	116
Table 5-1: Strategies for the treatment of Parkinson's disease .....	124
Table 5-2: Drug delivery systems for Parkinson's disease .....	126
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease .....	130

Table 5-4: Status of cell therapies in development for Parkinson's disease .....	130
Table 5-5: Gene therapy techniques applicable to Parkinson disease .....	136
Table 5-6: Companies developing gene therapy for Parkinson's disease.....	140
Table 5-7: Classification of pharmacotherapy for Alzheimer disease .....	141
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies .....	141
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	149
Table 5-10: Methods of delivery of therapies in development for ALS .....	150
Table 5-11: Classification of treatments for stroke .....	153
Table 5-12: Treatments of stroke involving innovative drug delivery methods .....	154
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty .....	156
Table 5-14: Gene transfer in animal models of carotid artery restenosis .....	163
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia .....	164
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models.....	165
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm.....	166
Table 5-18: Gene therapy strategies for vasospasm .....	167
Table 5-19: A classification of drug delivery methods used in management of pain .....	177
Table 5-20: Spinal administration of drugs for pain .....	182
Table 5-21: Investigational drugs for pain administered by intrathecal route .....	183
Table 5-22: Current management of migraine .....	188
Table 5-23: Novel drug delivery methods for migraine .....	189
Table 5-24: Innovative methods of drug delivery for glioblastoma multiforme .....	192
Table 5-25: Strategies for gene therapy of malignant brain tumors.....	202
Table 6-1: Share of drug delivery technologies in selected CNS markets: 2009-2019 .....	215
Table 6-2: CNS market share of drug delivery technologies 2009-2019 .....	215
Table 6-3: Value of CNS drug delivery in the major world markets from 2009-2019.....	216
Table 6-4: Limitations of the current drug delivery technologies for CNS.....	220
Table 7-1: Collaborations of companies in CNS drug delivery .....	299

## Figures

Figure 1-1: Interaction of neurotransmitters with receptors .....	19
Figure 2-1: The neurovascular unit .....	28
Figure 2-2: Various forms of passage of substances across the blood brain barrier.....	32
Figure 3-1: Routes of drug delivery to the brain .....	55
Figure 3-2: Use of receptor-mediated transcytosis to cross the BBB .....	75
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease .....	128
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels .....	137
Figure 5-3: A concept of targeted drug delivery to GBM across the BBB.....	198
Figure 6-1: Unmet needs in the CNS drug delivery technologies .....	220